Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1.
Xin LvZhen WangZhe WangHang YinYangliu XiaLili JiangYong Liu
Published in: Current drug metabolism (2024)
Avapritinib has the potential to cause intestinal DDIs via the inhibition of UGT1A1. Additional attention should be paid when avapritinib is coadministered with UGT1A1 substrates.